Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
68.64+0.04 (+0.06%)
At close: 04:00PM EDT
68.51 -0.13 (-0.19%)
After hours: 07:54PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Up

Gap Up

Performance Outlook
Previous Close68.60
Open68.84
Bid68.44 x 800
Ask68.76 x 900
Day's Range68.31 - 68.85
52 Week Range52.65 - 72.12
Volume4,330,312
Avg. Volume5,188,566
Market Cap213.623B
Beta (5Y Monthly)0.17
PE Ratio (TTM)64.75
EPS (TTM)1.06
Earnings DateN/A
Forward Dividend & Yield1.45 (2.11%)
Ex-Dividend DateFeb 23, 2023
1y Target Est77.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-23% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for AZN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Astrazeneca PLC
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, railroads may be in for a bumpy ride; ESG has some opportunities; biotechs innovate; and Constellation Brands, Autodesk, and Tencent.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Zacks

    Astrazeneca (AZN) Gains But Lags Market: What You Should Know

    In the latest trading session, Astrazeneca (AZN) closed at $68.64, marking a +0.06% move from the previous day.

  • Benzinga

    Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively

    Pieris Pharmaceuticals Inc (NASDAQ: PIRS) reported Q4 earnings and provided updates across its pipeline. The investors are reacting to the further pushback of the timeline for the readout from the Phase 2a study of elarekibep to mid-2024 from prior guidance of the third quarter of 2023. Pieris is collaborating with AstraZeneca Plc (NASDAQ: AZN) to develop elarekibep for asthma patients. AstraZeneca has communicated that completion of the Phase 2a study remains an important priority and that addi

  • Benzinga

    AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review

    Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results from the 66-week analysis of Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca Plc's (NASDAQ: AZN) eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) that leads to peripheral nerve damage and motor disability. At 66 weeks, patients treated with eplontersen demonstrated a statistically significant and clinically meaningful change from baseline versus an external placebo group on t

Advertisement
Advertisement